Juan Barcena

List of Publications by Year
in descending order

40 papers	1,521 citations	279798 23 h-index	315739 38 g-index
42 all docs	42 docs citations	42 times ranked	1391 citing authors

#	Article	IF	Citations
1	Immunogenicity of Multi-Target Chimeric RHDV Virus-Like Particles Delivering Foreign B-Cell Epitopes. Vaccines, 2022, 10, 229.	4.4	4
2	Development and Evaluation of a Duplex Lateral Flow Assay for the Detection and Differentiation between Rabbit Haemorrhagic Disease Virus Lagovirus europaeus/GI.1 and /GI.2. Biology, 2022, 11, 401.	2.8	2
3	Multiâ€event captureâ€“recapture models estimate the diagnostic performance of serological tests for myxoma and rabbit haemorrhagic disease viruses in the absence of reference samples. Transboundary and Emerging Diseases, 2022, 69, .	3.0	3
4	Chimeric RHDV Virus-Like Particles Displaying Foot-and-Mouth Disease Virus Epitopes Elicit Neutralizing Antibodies and Confer Partial Protection in Pigs. Vaccines, 2021, 9, 470.	4.4	5
5	An Adenovirus Vector Expressing FMDV RNA Polymerase Combined with a Chimeric VLP Harboring a Neutralizing Epitope as a Prime Boost Strategy to Induce FMDV-Specific Humoral and Cellular Responses. Pharmaceuticals, 2021, 14, 675.	3.8	3
6	Precise location of linear epitopes on the capsid surface of feline calicivirus recognized by neutralizing and non-neutralizing monoclonal antibodies. Veterinary Research, 2020, 51, 59.	3.0	13
7	Epidemiology of RHDV2 (Lagovirus europaeus/GI.2) in free-living wild European rabbits in Portugal. Transboundary and Emerging Diseases, 2018, 65, e373-e382.	3.0	41
8	Proposal for a unified classification system and nomenclature of lagoviruses. Journal of General Virology, 2017, 98, 1658-1666.	2.9	148
9	Rabbit hemorrhagic disease virus capsid, a versatile platform for foreign B-cell epitope display inducing protective humoral immune responses. Scientific Reports, 2016, 6, 31844.	3.3	11
10	Comparative analysis of rabbit hemorrhagic disease virus (RHDV) and new RHDV2 virus antigenicity, using specific virus-like particles. Veterinary Research, 2015, 46, 106.	3.0	41
11	Improved Production Efficiency of Virus-Like Particles by the Baculovirus Expression Vector System. PLoS ONE, 2015, 10, e0140039.	2.5	28
12	Structural Basis for the Development of Avian Virus Capsids That Display Influenza Virus Proteins and Induce Protective Immunity. Journal of Virology, 2015, 89, 2563-2574.	3.4	20
13	In vivo tracking and immunological properties of pulsed porcine monocyte-derived dendritic cells. Molecular Immunology, 2015, 63, 343-354.	2.2	13
14	Virus-like particle-based vaccines for animal viral infections. Inmunologia (Barcelona, Spain: 1987), 2013, 32, 102-116.	0.1	18
15	Design of Novel Vaccines Based on Virus-Like Particles or Chimeric Virions. Sub-Cellular Biochemistry, 2013, 68, 631-665.	2.4	30
16	B Epitope Multiplicity and B/T Epitope Orientation Influence Immunogenicity of Foot-and-Mouth Disease Peptide Vaccines. Clinical and Developmental Immunology, 2013, 2013, 1-9.	3.3	23
17	Virus-like particles: The new frontier of vaccines for animal viral infections. Veterinary Immunology and Immunopathology, 2012, 148, 211-225.	1.2	117
18	Chimeric calicivirus-like particles elicit specific immune responses in pigs. Vaccine, 2012, 30, 2427-2439.	3.8	36

#	Article	IF	Citations
19	Epitope Insertion at the N-Terminal Molecular Switch of the Rabbit Hemorrhagic Disease Virus T=3 Capsid Protein Leads to Larger T=4 Capsids. Journal of Virology, 2012, 86, 6470-6480.	3.4	25
20	Inclusion of a specific T cell epitope increases the protection conferred against foot-and-mouth disease virus in pigs by a linear peptide containing an immunodominant B cell site. Virology Journal, 2012, 9, 66.	3.4	20
21	Current strategies for subunit and genetic viral veterinary vaccine development. Virus Research, 2011, 157, 1-12.	2.2	63
22	Genome Comparison of a Nonpathogenic Myxoma Virus Field Strain with Its Ancestor, the Virulent Lausanne Strain. Journal of Virology, 2009, 83, 2397-2403.	3.4	27
23	Chimeric calicivirus-like particles elicit protective anti-viral cytotoxic responses without adjuvant. Virology, 2009, 387, 303-312.	2.4	26
24	Enhanced Mucosal Immunoglobulin A Response and Solid Protection against Foot-and-Mouth Disease Virus Challenge Induced by a Novel Dendrimeric Peptide. Journal of Virology, 2008, 82, 7223-7230.	3.4	92
25	Self-Assembly of the Recombinant Capsid Protein of a Swine Norovirus into Virus-Like Particles and Evaluation of Monoclonal Antibodies Cross-Reactive with a Human Strain from Genogroup II. Journal of Clinical Microbiology, 2008, 46, 3971-3979.	3.9	30
26	Towards a unique and transmissible vaccine against myxomatosis and rabbit haemorrhagic disease for rabbit populations. Wildlife Research, 2007, 34, 567.	1.4	34
27	Development of a low-cost, insect larvae-derived recombinant subunit vaccine against RHDV. Virology, 2007, 364, 422-430.	2.4	72
28	Synthesis in Vitro of Rabbit Hemorrhagic Disease Virus Subgenomic RNA by Internal Initiation on (â€“)Sense Genomic RNA. Journal of Biological Chemistry, 2004, 279, 17013-17018.	3.4	35
29	The coat protein of Rabbit hemorrhagic disease virus contains a molecular switch at the N-terminal region facing the inner surface of the capsid. Virology, 2004, 322, 118-134.	2.4	49
30	First field trial of a transmissible recombinant vaccine against myxomatosis and rabbit hemorrhagic disease. Vaccine, 2001, 19, 4536-4543.	3.8	40
31	Isolation of an attenuated myxoma virus field strain that can confer protection against myxomatosis on contacts of vaccinates. Archives of Virology, 2000, 145, 759-771.	2.1	22
32	Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease. Vaccine, 2000, 19, 174-182.	3.8	16
33	Horizontal Transmissible Protection against Myxomatosis and Rabbit Hemorrhagic Disease by Using a Recombinant Myxoma Virus. Journal of Virology, 2000, 74, 1114-1123.	3.4	72
34	Sequence and analysis of a swinepox virus homologue of the vaccinia virus major envelope protein P37 (F13L). Journal of General Virology, 2000, 81, 1073-1085.	2.9	10
35	Recombinant Swinepox Virus Expressing Î²-Galactosidase: Investigation of Viral Host Range and Gene Expression Levels in Cell Culture. Virology, 1998, 243, 396-405.	2.4	20
36	The Three Subunits of the Polymerase and the Nucleoprotein of Influenza B Virus Are the Minimum Set of Viral Proteins Required for Expression of a Model RNA Template. Virology, 1997, 235, 209-217.	2.4	37

#	Article	IF	Citations
37	Epitope mapping of cross-reactive monoclonal antibodies specific for the influenza A virus PA and PB2 polypeptides. Virus Research, 1995, 37, 305-315.	2.2	25
38	Complex structure of the nuclear translocation signal of influenza virus polymerase PA subunit. Journal of General Virology, 1994, 75, 29-36.	2.9	111
39	Monoclonal antibodies against influenza virus PB2 and NP polypeptides interfere with the initiation step of viral mRNA synthesis in vitro. Journal of Virology, 1994, 68, 6900-6909.	3.4	77
40	Nuclear transport of influenza virus polymerase PA protein. Virus Research, 1992, 24, 65-75.	2.2	62